Yulei Xia

Yulei Xia

Auto-generated profile, based on publicly available information

Yulei Xia

Department II of Neurology Affiliated Hospital of Shandong Second Medical University Weifang China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2024 in European Journal of Neurology
Verified
Journal Article
Open access
SHShuai Hou
Shuai Hou
YZYifeng Zhang
Yifeng Zhang
YXYulei Xia
Yulei Xia
YLYong Liu
Yong Liu
XDXia Deng
Xia Deng
GWGang Wang
Gang Wang
Background and purpose: This study aims to examine the global, regional, and national burden of ischemic stroke from 1990 to 2021.Method: We used data from the Global Burden of Disease (GBD) 2021 database to comprehensively assess ischemic stroke indicators globally, regionally, and in 204 countries, including incidence, deaths, disability‐adjusted life years (DALYs), estimated annual percentage change (EAPC), and Joinpoint regression analysis.Results: In 2021, there were a total of 7,804,449 cases of ischemic stroke globally (95% uncertainty interval = 6,719,760–8,943,692), with an age‐standardized incidence rate (ASIR) of 92.39. This represents a declining trend compared to 1990, with an EAPC of −0.67 (95% confidence interval [CI] = −0.76 to −0.58). Mortality and DALY rates also showed a downward trend (EAPC in age‐standardized mortality rate: −1.83, 95% CI = −1.92 to −1.74; EAPC in age‐standardized DALY rate = −1.59, 95% CI = −1.68 to −1.50). The burden of ischemic stroke was inversely correlated with gross domestic product. Regionally, from 2014 to 2021, the Caribbean experienced the fastest increase in ASIR (annual percent change = 0.15, 95% CI = 0.13 to 0.18). Among 204 countries, North Macedonia had the highest incidence, mortality, and DALY rates. In addition to metabolic risks, particulate matter pollution and low temperatures were significant environmental and occupational risk factors for ischemic stroke. Smoking and a diet high in sodium were identified as key behavioral risk factors.Conclusions: Ischemic stroke remains a serious global health challenge, and our results from this cross‐sectional study suggest that the burden of disease remains high in Eastern Europe, East Asia, Central Asia, and Sub‐Saharan Africa.

22 October 2026 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
YXYulei Xia
Yulei Xia
YZYifeng Zhang
Yifeng Zhang
XWXiaolu Wang
Xiaolu Wang
HYHang Yang
Hang Yang
SHShuai Hou
Shuai Hou
YWYanqiang Wang
Yanqiang Wang
Objective: Parkinson’s Disease (PD) is a progressive neurodegenerative disorder characterized by nigrostriatal dopaminergic neuronal loss, neuroinflammation, oxidative stress, and motor dysfunction. Current therapies mainly provide symptomatic relief, whereas effective disease-modifying strategies remain limited. Yindan Xinnaotong soft capsule (YDXNT), a multi-component Chinese patent medicine, has shown neuroprotective potential, but its pharmacological effects in PD remain insufficiently understood. This study aimed to investigate the neuroprotective effects of YDXNT and identify signaling pathways potentially involved in its actions against experimental PD-related pathology. Methods: Network pharmacology was used to identify candidate bioactive compounds, therapeutic targets, and enriched pathways of YDXNT in PD. Molecular docking was performed to predict interactions between representative compounds and core targets. The predicted mechanisms were further evaluated in vivo using MPTP-induced parkinsonian mice and in vitro using MPP+-treated BV-2 microglial cells. Behavioral testing, TH and Iba-1 staining, ELISA, RT-qPCR, and Western blotting were used to assess motor function, dopaminergic injury, microglial activation, neurotrophic factors, and pathway-related molecular changes. Results: Seven representative compounds—β-sitosterol, cryptotanshinone, isogoycyrol, isorhamnetin, kaempferol, luteolin, and quercetin—were prioritized as candidate bioactive constituents. PI3K, AKT, MDM2, and p53 were identified as core pathway-related targets, and molecular docking predicted favorable compound–target interactions, with binding energies below −6 kcal/mol. YDXNT improved motor performance, preserved TH-positive neurons and striatal fibers, and reduced Iba-1-positive microglial activation in MPTP-treated mice. High-dose YDXNT also increased BDNF, GDNF, and CDNF levels. In animal tissues and BV-2 cells, YDXNT increased PI3K and AKT phosphorylation and MDM2 expression while reducing p53 expression. Discussion: These findings suggest that YDXNT may exert neuroprotective effects through coordinated regulation of dopaminergic neuronal integrity, microglial activation, neurotrophic support, and cell-survival signaling. The convergence of network pharmacology, molecular docking, and experimental findings supports the possible involvement of the PI3K/AKT/MDM2/p53 signaling axis; however, the current evidence demonstrates association rather than pathway causality, and direct target engagement requires further validation. Conclusion: YDXNT ameliorates experimental PD-related pathology through multi-component and multi-target actions associated with the regulation of the PI3K/AKT/MDM2/p53 signaling axis, supporting its further investigation as a potential neuroprotective strategy for PD.